Value Sense
SPRY

ARS Pharmaceuticals, Inc. (SPRY)

Last Price$12.94.3%
Market Cap$1,249.5M

SPRY Rating

SPRY Quality rating
6.2
How this score works?
SPRY Quality rating performance

SPRY Intrinsic Value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 24, 2025 SPRY Relative Value is $9.9, which is overvalued by 23.2%, compared to current share price of $12.9.
DCF Value vs Current Share Price
As of Mar 24, 2025 SPRY DCF Value is N/A, which is undervalued by N/A, compared to current share price of $12.9.
Methodology
Price per share, $
SPRY
Intrinsic value$9.9
Overvalued by22.9%
Current share price
12.9
Relative value
9.9
DCF value
not available

SPRY Share Price History

1W 12.7%
1M 19.0%
6M (5.8%)
YTD 131.0%
1Y 41.2%
3Y 234.8%
5Y (48.4%)
10Y (48.4%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!

SPRY Stock Metrics

Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
Market Cap
$1,249.5M
Enterprise Value
$935.5M
LTM Revenue
$89.1M
LTM Free Cash Flow
$13.0M
Shares Outstanding
97M
Employees
N/A
Growth (CAGR)
Revenue 5Y
N/A
Operating Income 5Y
N/A
EPS 5Y
N/A
Free Cash Flow 5Y
N/A
Forward Revenue 2Y
28,166.7%
Forward EPS 2Y
15.44%
Profitability
Gross margin
98.9%
EBIT margin
(3.5%)
Net income margin
9.0%
OCF margin
15.2%
FCF margin
14.6%
FCF / Net Income
162.4%
Intrinsic Value
Intrinsic Value
$9.9 (22.9% overvalued)
DCF Value
N/A
Relative Value
$9.9
Peter Lynch fair value
($0.2)
Ben Graham fair value
$1.5
Reverse DCF (implied FCF growth)
28.2%
EPV, % of EV
(3.3%)
Valuation (LTM)
EV / Revenue
10.5x
EV / EBIT
(303.4x)
P / FCF
96.2x
P / E
156.2x
P / BV
4.9x
PEG
10.1x
FCF Yield
1.0%
Return on Capital
ROE
3.5%
ROA
2.8%
ROIC
(49.6%)
ROCE
(1.3%)
ROE 5Y avg
10.8%
ROIC 5Y avg
(5,662.7%)
ROCE 5Y avg
(5,662.7%)
Financial Health
Cash & Short-term Investments
$314.0M
Net Debt
($314.0M)
Net Debt / FCF
(24.2x)
EBIT / Interest
N/A
Total Debt / Equity
0.0%
Dividends
Dividends per share (DPS)
$0.0
DPS 5Y CAGR
N/A
Dividend Yield
0.0%
FCF Payout ratio
0.0%
Ex-dividend date
Earnings
Next earnings date
May 07, 2025
Last Revenue surprise
MISS by (725.8%)
Last EPS surprise
MISS by 10.0%
Next EPS YoY growth
100.0%
Last 10 earnings
4 Beat & 6 Miss

SPRY Stock Financials

SPRY Income Statement Metrics

Annual
Quarterly
LTM

Revenue

$30.0K -97.7% YoY

Operating Income

($67,520.0K) +90.1% YoY

Net Income

($54,365.0K) +60.0% YoY

SPRY Cash Flow Statement Metrics

Annual
Quarterly
LTM

Operating Cash Flow (OCF)

($59.3M) +47.9% YoY

Capital Expenditure (CAPEX)

($175.0K) -12.1% YoY

Free Cash Flow (FCF)

($59.4M) +47.6% YoY

SPRY Income Statement Overview

Annual
Quarterly
LTM
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Revenue
$30.0K (97.7%) YoY
Gross profit
$43.0K (99.7%) YoY
(143.3%) margin
Cost of revenue
$73.0K (99.6%) YoY
Operating expenses
$67.6M 83.4% YoY
Net income
$54.4M 60.0% YoY
(181,216.7%) margin
Other: $54.4M
R&D
$20.3M 10.3% YoY
67,553.3% of revenue
SG&A
$47.3M 156.2% YoY
157,613.3% of revenue

SPRY Balance Sheet Overview

Annual
Quarterly
LTM
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$233.2M
Current assets ($231.7M, 99.4% of total)
Cash & ST investments
$228.4M (97.9%)
Accounts receivables
$795.0K (0.3%)
Other current assets
$2,571.0K (1.1%)
Non-current assets ($1,462.0K, 0.6% of total)
Intangible assets
$617.0K (0.3%)
Other non-current assets
$21.0K (0.0%)
Financial position
Net Debt
($228.1M)
$228.4M$274.0K
Cash & Short-term Investments
Total Debt
Quick ratio
95.8x
Net Debt to Free Cash Flow
3.8x
Debt to Equity ratio
0.1%

SPRY Stock Ratios

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Revenue growth
EPS growth
Gross margin
Free Cash Flow margin
Net Debt to FCF
FCF to Interest
ROIC
Shareholder yield

SPRY Earnings Surprises

Crunching data... Almost there!

SPRY Dividends

SPRY Dividend Yield

Crunching data... Almost there!

SPRY Dividend Per Share

3Y
10Y
30Y
Annual
Quarterly
LTM
1Y Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
10Y CAGR
N/A

Competing with SPRY

Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name
Market Cap
Quality rating
Intrinsic value
1Y Return
Revenue
Free Cash Flow
Revenue growth
FCF margin
Gross margin
ROIC
Total Debt to Equity
SPRY
$1,249.5M
6.2
$9.9
22.9% overvalued
41.2%
$89.1M
$13.0M
N/A
14.6%
98.9%
(49.6%)
0.0%
VRTX
$131.8B
5.8
$186.0
63.7% overvalued
23.0%
$11.0B
($790.3M)
11.5%
(7.2%)
86.1%
(15.0%)
10.7%
REGN
$71.1B
6.4
$1,034.1
56.4% undervalued
(31.1%)
$14.2B
$3,597.2M
8.3%
25.3%
84.5%
25.7%
5.7%
ARGX
$43.1B
6.3
$161.4
73.4% overvalued
52.6%
$3,154.8M
($58.8M)
157.1%
(1.9%)
74.8%
67.0%
0.7%
ALNY
$37.4B
5.2
$92.7
68.1% overvalued
91.2%
$2,248.2M
($42.6M)
23.0%
(1.9%)
85.6%
(7.2%)
1,931.9%
BNTX
$24.2B
6.0
$193.7
92.5% undervalued
8.2%
€2,751.1M
(€229.8M)
(28.0%)
(8.4%)
80.3%
(37.8%)
1.3%
RPRX
$15.1B
5.5
$68.9
104.3% undervalued
14.9%
$2,263.9M
$2,769.0M
(3.8%)
122.3%
73.9%
14.5%
73.6%
SMMT
$15.0B
6.0
$0.6
97.2% overvalued
530.8%
$0.0
($142.1M)
N/A
N/A
N/A
(3,335.4%)
1.9%
UTHR
$14.3B
7.8
$542.3
69.6% undervalued
31.0%
$2,877.4M
$1,080.6M
23.6%
37.6%
89.2%
65.4%
4.7%
BMRN
$13.7B
6.8
$50.8
29.4% overvalued
(16.8%)
$2,850.5M
$475.4M
17.8%
16.7%
78.6%
11.0%
10.7%
BGNE
$1,846.9M
5.5
$2,609.6
1,051.1% undervalued
39.9%
$3,316.8M
($1,041.0M)
50.5%
(31.4%)
83.7%
(43.2%)
32.1%

FAQ

What is ARS Pharmaceuticals, Inc. (SPRY) stock rating?

As of today, ARS Pharmaceuticals, Inc. has a stock rating of 6 (out of 10), which is considered Good.

is ARS Pharmaceuticals, Inc. (SPRY) a good stock to buy?

As of today, ARS Pharmaceuticals, Inc. has a Good stock rating, which is 22.9% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.